Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion.

Of interest, NKG2D, an activating receptor also expressed by most Vγ9Vδ2 T-cells, remained highly expressed when Vγ9Vδ2 T-cells were expanded with pamidronate or the TAA-Vδ2 hi-lo bsVHH, but was expressed by a lower proportion of Vγ9Vδ2 T-cells when these were expanded with the TAA-Vδ2 hi-lo bsVHH-Fc engagers, though this did not reach statistical significance.

also in 111,027 other papers